Today News

Testing finds this recalled drug may have deadly bacterial contamination

A drug used to treat a type of pneumonia has been recalled after tests found it could be as deadly as the infection it treats.

AvKARE is recalling a batch of atovaquone oral suspension after third-party testing revealed possible Bacillus cereus contamination in the drug.

As for what this means, the risk statement in the AvKARE recall notice states: “In the most at-risk populations, those who are immunocompromised, microbial contamination of atovaquone oral suspension is likely to result in disseminated, Life-threatening infections such as endocarditis and necrotizing soft tissue infections.”

The Mayo Clinic explains that endocarditis is an “inflammation of the lining of the heart.” inner wall of ventricle According to Johns Hopkins University Medical Center, “necrotizing soft tissue infection” is a serious, life-threatening condition that requires immediate treatment to prevent infection. Destroys skin, muscles and other soft tissues”.

AvKARE only extracted Atovaquone Oral Suspension, USP 750mg/5mL, with batch number AW0221A and expiry date 08/2025. The NDC number and UPC number are game-5026808612-but the NDC number is divided into three parts, with the eighth number after the fifth number. The medicine was distributed to wholesalers across the country from March 18 to March 21.

Packaging of atovaquone oral suspension.

Packaging of atovaquone oral suspension.

Medicines are packed in cartons. If you have this medicine, stop using it immediately. Then either throw it away or return it to the store for a refund.

If you have an adverse reaction to a medicine, call your medical professional.Then Contact FDA’s MedWatch Program Online or call 800-332-1088.

For recall questions please contact AvKARE at 855-361-3993 or drugsafety@avkare.comMonday through Friday, 9 a.m. to 5 p.m. Eastern Time.

Carton of atovaquone oral suspension.Carton of atovaquone oral suspension.

Carton of atovaquone oral suspension.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button